Zolucatetide

N/A

Report date: 2026/05/13 16:54:03

NME

Base Information

Drug NameZolucatetide

Drug Alias Name2,2'-((1''S,2R,2'S,5'S,8'S,10''E,12'Z,18''S,21''S,27''S,30''S,33''S,42''S,45''S,48''S)-1-acetyl-42''-(((S)-1-amino-1-oxopropan-2-yl)carbamoyl)-45''-(benzo[b]thiophen-3-ylmethyl)-30''-benzyl-21''-(3-carboxybenzyl)-24'',24'',27''-trimethyl-5'-neopentyl-3',5'',6',16',16'',19'',22'',25'',28'',31'',39'',44'',47'',50'',52''-pentadecaoxo-48''-(thiophen-3-ylmethyl)-6''-oxa-1',4',4'',7',17'',20'',23'',26'',29'',32'',38'',43'',46'',49'',51''-pentadecaazadispiro[pyrrolidine-2,15'-cyclohexadecane-8',15''-tFOG-001

ClassificationSmall molecules > Synthetic peptide

Mechanisms of ActionCatenin beta 1 inhibitorsTranscription factor 4 inhibitors

TargetsCatenin beta 1Transcription factor 4

Therapy Area/IndicationsSolid tumoursMicrosatellite instability-high cancerNeoplasm Metastasis +[12]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaIND

Originator CompaniesParabilis Medicines Inc

China Registration ClassN/A

Develop Information

Active CompaniesParabilis Medicines Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursMicrosatellite instability-high cancerNeoplasm Metastasis +[11]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A